The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...

Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic version of ...

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favora ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through ...

US FDA extends review period for Bayer’s NDA for elinzanetant to treat moderate to severe VMS due to menopause: Berlin Monday, July 28, 2025, 16:00 Hrs [IST] Bayer announced tha ...

For example, a cancer patient can now buy a locally produced immunity boosting drug for Tk 7,000-8,000 per pre-filled syringe, while the imported version would cost Tk 85,000-95,000. Experts note that ...

Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

The Supreme Court’s recent unanimous decision on FDA’s tobacco-authorization authority is utterly unremarkable.

Researchers at the National University of Singapore (NUS) have found new applications of magnetic field therapy with ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.